United States. Food and Drug Administration, Center for Devices and Radiological Health. *510(k) Substantial Equivalence Determination Decision Summary: INNOVANCE D-Dimer.* K091916. 5 pp. Cited as FDA 510(k) K091916. Printed and file pagination coincide.
Source map
The book’s source trail, chapter by chapter.
Entries are carried from the frozen manuscript bibliography. Page references in the book follow printed pages, reporter pages, statutory provisions or paragraph numbers shown by the source documents; missing dates were not reconstructed.
Chapter 1
Chapter 2
United States. Nuclear Regulatory Commission. "Acceptance Criteria for Emergency Core Cooling Systems for Light-Water Nuclear Power Reactors." 10 C.F.R. § 50.46, annual edition dated 1 January 2025; live eCFR checked 28 July 2026. Cited as 10 C.F.R. § 50.46. Printed pages 889–891 appear at electronic-file pages 47–49. (accessed 28 July 2026).
United States. Atomic Energy Commission. "Acceptance Criteria for Emergency Core Cooling Systems for Light Water Nuclear Power Reactors." 39 Fed. Reg. 1002–1003 (4 January 1974). Cited as AEC 1974 ECCS Final Rule. The cited pages appear at electronic-file pages 5–6. (accessed 28 July 2026).
United States. Nuclear Regulatory Commission. "Emergency Core Cooling Systems; Revisions to Acceptance Criteria." 53 Fed. Reg. 35996–36006 (16 September 1988). Cited as NRC 1988 ECCS Revisions. (accessed 28 July 2026).
United States. Nuclear Regulatory Commission. "Emergency Core Cooling System Evaluation Models." 65 Fed. Reg. 34913–34921 (1 June 2000). Cited as NRC 2000 ECCS Evaluation Models. (accessed 28 July 2026).
United States. Nuclear Regulatory Commission. Amendments affecting 10 C.F.R. § 50.46 and cited in note c2-13: 57 Fed. Reg. 39358 (31 August 1992); 61 Fed. Reg. 39299 (29 July 1996); 62 Fed. Reg. 59276 (3 November 1997); and 72 Fed. Reg. 49494 (28 August 2007). Official daily issues: (accessed 6 August 2026).
United States. Nuclear Regulatory Commission. "Calculated Maximum Fuel Element Cladding Temperature." 86 Fed. Reg. 1022–1030 (7 January 2021), petitions PRM-50-93 and PRM-50-95. Cited as NRC 2021 ECCS Petition Denial. (accessed 28 July 2026).
United States. Food and Drug Administration, Center for Drug Evaluation and Research. *Guidance for Industry: Hypertension Indication—Drug Labeling for Cardiovascular Outcome Claims.* March 2011. 12 pp. Cited as *Hypertension Outcome-Claims Guidance*. (accessed 6 August 2026).
Blood Pressure Lowering Treatment Trialists' Collaboration. "Pharmacological Blood Pressure Lowering for Primary and Secondary Prevention of Cardiovascular Disease across Different Levels of Blood Pressure: An Individual Participant-Level Data Meta-analysis." *The Lancet* 397 (2021): 1625–1636. PII S0140-6736(21)00590-0. Cited as BPLTTC.
Chapter 3
Organ Procurement and Transplantation Network. *Modify Waiting Time for Candidates Affected by Race-Inclusive Estimated Glomerular Filtration Rate (eGFR) Calculations.* Public-comment proposal, 2022. Cited as *eGFR Waiting-Time Modification Proposal*. Printed and file pagination coincide. (accessed 6 August 2026).
Organ Procurement and Transplantation Network. *Establish OPTN Requirement for Race-Neutral eGFR Calculations: Notice of Policy Change.* 2022. Cited as *Race-Neutral eGFR Policy Notice*. Printed and file pagination coincide. (accessed 6 August 2026).
Organ Procurement and Transplantation Network, Minority Affairs Committee. *1 Year Waiting Time Modification Monitoring Report.* 8 April 2024. Cited as *One-Year eGFR Monitoring Report*. Printed and file pagination coincide. (accessed 6 August 2026).
Organ Procurement and Transplantation Network, Patient Affairs Committee. *Patient Affairs Committee Meeting Summary, 16 April 2024.* 16 April 2024. Cited as *Patient Affairs Summary*. Printed and file pagination coincide. (accessed 6 August 2026).
Health Resources and Services Administration, Organ Procurement and Transplantation Network. “Waiting Time Modifications for Candidates Affected by Race-Inclusive eGFR Calculations.” Policy summary, last reviewed December 2025. Cited in note c3-64 for continuing Policy 3.7.D duties after the initial implementation deadline. (accessed 6 August 2026).
Organ Procurement and Transplantation Network, Minority Affairs Committee. *Monitor Ongoing eGFR Modification Policy Requirements: Notice of Policy Change.* Board approved 9–10 June 2025; effective 10 September 2025. Cited in note c3-64. (accessed 6 August 2026).
Chapter 4
United States. Centers for Medicare & Medicaid Services. *Skilled Nursing Facility 3-Day Rule Billing.* MLN9730256. May 2026. 7 pp. Cited as *SNF 3-Day Rule Billing*. Printed and file pagination coincide. (accessed 6 August 2026).
United States. *United States Code*, title 42, § 1395x(h)–(k). Cited by statutory subsection.
United States. Centers for Medicare & Medicaid Services. "Medicare Program; Appeal Rights for Certain Changes in Patient Status." 89 Fed. Reg. 83240–83294 (15 October 2024); correcting amendment, 89 Fed. Reg. 106362–106364 (30 December 2024). Cited as *Patient-Status Appeals Final Rule*. correction: (accessed 28 July 2026).
Chapter 5
United States. Supreme Court. *Utah v. Evans.* 536 U.S. 452 (2002). Cited as *Utah v. Evans* and by United States Reports page.
United States. District Court for the District of Utah. *Utah v. Evans.* 182 F. Supp. 2d 1165 (D. Utah 2001), No. 01CV292. Cited as *Utah v. Evans* (D. Utah).
United States. *United States Code*, title 2, § 2a, "Reapportionment of Representatives." Cited as 2 U.S.C. § 2a.
United States. Census Bureau. "Computing Apportionment." Revised 22 November 2021. Cited as "Computing Apportionment." (accessed 23 July 2026).
Epstein, Brynn, and Daphne Lofquist. *Congressional Apportionment: 2020 Census Briefs.* C2020BR-01. United States Census Bureau, May 2023. 9 pp. Cited as *Congressional Apportionment*. (accessed 6 August 2026).
Hill, Courtney, Krista Heim, Jinhee Hong, and Nam Phan. *2020 Post-Enumeration Survey Estimation Report—Census Coverage Estimates for People in the United States by State and Census Operations.* PES20-G-02RV. United States Census Bureau, June 2022. Cited as *2020 Post-Enumeration Survey Estimation Report*. (accessed 6 August 2026).
Chapter 6
Japan. Ministry of the Environment. *History and Overview of Decontamination Projects.* Chapter 1 of the 2019 decontamination-projects report. Cited as *History and Overview of Decontamination Projects*. Printed chapter pages 1–8 appear at electronic-file pages 21–28 of the original report. (accessed 6 August 2026).
International Atomic Energy Agency. *Final Report: The Follow-up IAEA International Mission on Remediation of Large Contaminated Areas Off-Site the Fukushima Daiichi Nuclear Power Plant.* 2014. Cited as *Follow-up Remediation Mission*. Notes cite report pages 5–6 and 16–18. (accessed 6 August 2026).
Chapter 7
Isthmian Canal Commission. *The Canal Record.* Vol. VIII, no. 7, 30 September 1914. Cited as *The Canal Record* (30 Sept. 1914). Printed page 66 appears at source-scan file page 72 and at page 1 of the local page reproduction. (accessed 28 July 2026).
Panama Canal Authority. *Regulations for the Admeasurement of Vessels to Assess Tolls for Use of the Panama Canal.* 2019 ed. Cited as *Admeasurement Regulations*. (accessed 28 July 2026).
Panama Canal Authority. *Maritime Services Tariffs.* February 2026 ed. 14 pp. Cited as *Maritime Services Tariffs*. (accessed 28 July 2026).
Panama Canal Authority. *Notes on Tolls Tariffs & Maritime Services.* February 2026 ed. Cited as *Notes on Tolls*. (accessed 28 July 2026).
Chapter 8
Valukas, Anton R., Examiner. *Report of Anton R. Valukas, Examiner, In re Lehman Brothers Holdings Inc.* Vol. 3. Bankruptcy S.D.N.Y. Case No. 08-13555. 2010. Cited as *Lehman Examiner Report*, vol. 3. Notes cite the printed report pagination. (accessed 28 July 2026).
Lehman Brothers Holdings Inc. *Annual Report on Form 10-K for the Fiscal Year Ended November 30, 2007.* SEC accession 0001104659-08-005476. 2008. Cited as Lehman 2007 Form 10-K and by filing page. (accessed 28 July 2026).
Financial Accounting Standards Board. *Statement of Financial Accounting Standards No. 140: Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities.* September 2000. Cited as FASB Statement No. 140 and by paragraph number. (accessed 28 July 2026).
Lehman Brothers Holdings Inc. *Quarterly Report on Form 10-Q for the Quarter Ended February 29, 2008.* SEC accession 0001104659-08-023292. 2008. Cited as Lehman Q1 2008 Form 10-Q. (accessed 28 July 2026).
Lehman Brothers Holdings Inc. *Quarterly Report on Form 10-Q for the Quarter Ended May 31, 2008.* SEC accession 0001104659-08-045115. 2008. Cited as Lehman Q2 2008 Form 10-Q. Note citations use filing page 89. (accessed 28 July 2026).
US Foods, Inc. *ABL Credit Agreement.* Exhibit 10.1, agreement dated 31 May 2019. SEC accession 0000950157-19-000695. Cited as US Foods ABL Credit Agreement. (accessed 6 August 2026).
United States. Board of Governors of the Federal Reserve System. "Regulations Implementing the Adjustable Interest Rate (LIBOR) Act." Regulation ZZ, Docket No. R-1775, 88 Fed. Reg. 5204 (26 January 2023). Cited as Regulation ZZ Final Rule. (accessed 28 July 2026).
United States. Board of Governors of the Federal Reserve System. "Regulation ZZ—Regulations Implementing the Adjustable Interest Rate (LIBOR) Act." 12 C.F.R. Part 253, effective 27 February 2023. Cited as 12 C.F.R. Part 253. (accessed 28 July 2026).
United States. *United States Code*, title 12, § 5804, "Continuity and Safe Harbor Provisions." Cited as 12 U.S.C. § 5804. (accessed 28 July 2026).
Chapter 9
United States. Department of Veterans Affairs, Office of Inspector General. *Review of Alleged Patient Deaths, Patient Wait Times, and Scheduling Practices at the Phoenix VA Health Care System.* Report no. 14-02603-267. Washington, DC, 26 August 2014. 143 pp. Cited as *Phoenix Review*. In the electronic file, printed body page *n* appears at file page *n* + 10, and the front matter printed i–v appears at file pages 5–9. (accessed 28 July 2026).
United States. Department of Veterans Affairs, Office of Inspector General. *Administrative Summary of Investigation Regarding Patient Wait Times at the Phoenix VA Medical Center.* Report no. 14-02890-126. Washington, DC, 2017. 30 pp. Cited as *Phoenix Investigation Summary*. Printed and file pagination coincide. (accessed 28 July 2026).
United States. Food and Drug Administration. Accelerated approval letter, new drug application 214383, Pepaxto (melphalan flufenamide) for injection. 26 February 2021. 8 pp. Cited as *Pepaxto* approval letter. Printed and file pagination coincide. (accessed 28 July 2026).
United States. Food and Drug Administration. *Final Decision on the Proposal to Withdraw Approval of Pepaxto (melphalan flufenamide) for Injection.* Docket no. FDA-2023-N-3167. 23 February 2024. 25 pp. Cited as *Pepaxto* final decision. Printed and file pagination coincide. (accessed 28 July 2026).
United States. Food and Drug Administration. "Pepaxto (melphalan flufenamide) for Injection; Withdrawal of Approval of a New Drug Application." *Federal Register* 89, no. 76 (18 April 2024): 27766–27767. FR Doc. 2024-08274. Cited as *Pepaxto* withdrawal notice. Cited by *Federal Register* page. (accessed 28 July 2026).